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OBJECTIVE — We tested whether determination of the ACE insertion/deletion polymor-
phism is useful for renal and cardiovascular prognoses of type 2 diabetic subjects.
RESEARCH DESIGN AND METHODS — The French participants (3,126 of 4,912) in
the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardio-
vascular Events, and Ramipril (DIABHYCAR) trial were studied for their prognosis over 4 years
according to their ACE insertion/deletion polymorphism. We used two cohorts of French type 2
diabetic patients for replication: a 3-year follow-up study (n  917; Survie, Diabete de type 2 et
Genetique[SURDIAGENE]study)andacase-controlstudyondiabeticnephropathy(n1,277;
Diabete de type 2, Nephropathie et Genetique [DIAB2NEPHROGENE] study). We investigated
the effect of the insertion/deletion polymorphism on the primary outcome in the DIABHYCAR
trial (deﬁned as the ﬁrst of the following events to occur: cardiovascular death, nonfatal myo-
cardial infarction, stroke, heart failure leading to hospital admission, or end-stage renal failure)
and its components.
RESULTS — In DIABHYCAR, the primary outcome and most of its components were not
affected by the ACE insertion/deletion genotype. Only renal outcome was favored by the I allele
(P  0.03). The risk of myocardial infarction was not affected by ACE genotype, but the
probabilityoffataloutcomeincreasedwiththenumberofDalleles(P0.03).InSURDIAGENE,
the association between the ACE I allele and
renal outcome was not replicated. In
DIAB2NEPHROGENE, no association was
found with nephropathy.
CONCLUSIONS — We were not able to
demonstrate the manifest usefulness of the
ACE insertion/deletion polymorphism for the
prognosis of type 2 diabetic subjects.
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T
he reduced life expectancy of dia-
betic subjects is due mostly to renal
and cardiovascular outcomes (1).
Renal risk threatens type 1 diabetic sub-
jects, whereas cardiovascular risk is typi-
caloftype2diabetes.However,thesetwo
risks are intimately linked, as microalbu-
minuriaispredictiveofdiabeticnephrop-
athy in type 1 diabetes (2) and of
cardiovascular death principally in type 2
diabetes (3). Microalbuminuria, a marker
of early renal involvement, indicates gen-
eralized vascular leakage and endothelial
dysfunction(4),likelytopromotecardio-
vascular events.
ACE regulates microcirculation
within the kidney and myocardium by
generating angiotensin 2, a vasoconstric-
tor peptide with proﬁbrotic and proco-
agulantproperties,andbybreakingdown
kinins, which have the opposite proper-
ties (5). Pharmacological inhibition of
ACE protects against renal and cardiovas-
cular risks in diabetes: it protects against
nephropathy(6)andlimitsprogressionto
end-stage renal failure (ESRF) (7) mostly
in type 1 diabetes, whereas it reduces car-
diovascular risk (mainly by protecting
against coronary heart disease) in type 2
diabetes (8). Interestingly, the doses of
ACEinhibitorsrequiredtoreducecardio-
vascular risk are higher than those re-
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and renal risk (10).
The ACE gene is an excellent candidate
for determining prognosis for cardiovascu-
lar and renal risks: a single insertion/
deletion polymorphism in intron 16
(rs1799752) of a 287-bp Alu sequence ac-
counts for half of the interindividual vari-
anceofthecirculatingandcellularactivities
of this enzyme. ACE activity is highest in
subjects homozygous for the D allele (DD
genotype), lowest in those homozygous for
the I allele (II genotype), and intermediate
in heterozygotes (ID genotype). Although
its prognostic value for myocardial infarc-
tion is controversial in the general popula-
tion (11,12), its impact for renal prognosis
is well established in type 1 diabetes (13–
16). Clinical trials in type 1 diabetes have
suggested that patients with the II genotype
display a better renal response to ACE inhi-
bition than other patients (17).
We therefore wondered whether
genotyping ACE for its insertion/deletion
polymorphism would markedly contrib-
ute to individualization of renal and car-
diovascular prognoses of type 2 diabetic
subjects with raised urinary albumin
concentrations in a substudy of the
Non-Insulin-Dependent Diabetes, Hy-
pertension,MicroalbuminuriaorProtein-
uria,CardiovascularEvents,andRamipril
(DIABHYCAR) trial (9), a clinical trial
comparing a low dose of ramipril with
placebo. We assessed the impact of the
ACE insertion/deletion genotype on the
principaloutcome,acompositeofcardio-
vascular death, nonfatal myocardial in-
farction, stroke, heart failure leading to
hospitalization, and ESRF, and on each of
its components. To replicate our initial
ﬁndings, we tested the same hypothesis
on two independent cohorts of French
type 2 diabetic patients: a single-center
follow-upstudyoncardiovascularandre-
nal outcomes (the Survie, Diabete de type
2 et Genetique [SURDIAGENE] study),
and a multicenter case-control study on
diabetic nephropathy (the Diabete de
type 2, Nephropathie et Genetique
[DIAB2NEPHROGENE] study).
RESEARCH DESIGN AND
METHODS
Primary cohort
The DIABHYCAR study design and re-
sults have been reported elsewhere
(9,18). Participants were selected on the
basis of type 2 diabetes, treatment with
oral antidiabetic agents on enrollment,
highurinaryalbuminconcentration(76%
microalbuminuric and 24% macroalbu-
minuric patients), age 50 years, and se-
rum creatinine concentration 150
mol/l. French patients were selected by
their general practitioners, and 98%
were Caucasians. The tested drug was
low-dose ramipril (1.25 mg/day). The
primary end point was the combined in-
cidence of cardiovascular death, nonfatal
acute myocardial infarction, stroke, heart
failure leading to hospitalization, and
ESRF (deﬁned as a requirement for dialy-
sis or kidney transplant). These outcomes
were also analyzed separately. All events
were adjudicated by an independent clin-
ical event committee (18). Ramipril
proved to be ineffective (9).
The genetic substudy of DIABHYCAR
was conducted in the French participants
only for logistic reasons. All gave written
consent on a form separate from the trial
consent form. As preliminary data had sug-
gested that an ACE insertion/deletion poly-
morphismmightbeassociatedwiththerisk
of myocardial infarction (11) and diabetic
nephropathy (19), this analysis was
planned prospectively (20). By assuming a
D allele frequency of 60% and a composite
event rate of 20% over the study period
(20), the sample size of the French sub-
group (18) gave an a priori power of 94%
for detecting a 25% difference in the risk of
morbid events among patients with the DD
genotype and those with the ID or II geno-
type.Thestudydesignwasapprovedbythe
Angers University Ethics Committee.
Replication cohorts
SURDIAGENE was a prospective single-
center follow-up study of type 2 diabetic
patientsregularlybeingseenattheDiabe-
tes Department at Poitiers University
Hospital, in 2001–2007, designed to
identify the genetic determinants of mi-
crovascular and macrovascular diabetic
complications in type 2 diabetes. The
main exclusion criteria were residence
outside the Poitiers area and/or evidence
of nondiabetic kidney disease. Clinical
events corresponding to the primary end
point of the DIABHYCAR study were re-
corded prospectively from patients’ hos-
pital records and interviews with general
practitioners.
DIAB2NEPHROGENE was a multi-
center case-control study (15 diabetes
and 5 nephrology centers in France be-
tween 2001 and 2004 [additional informa-
tion can be found in an online appendix at
http://dx.doi.org/10.2337/dc07-2079]) de-
signed to assess the genetic determinants of
diabetic nephropathy in type 2 diabetes.
Case patients were type 2 diabetic patients
with high urinary albumin concentrations
(20 mg/l or 30 mg/24 h on two of three
sterile urine collections) and retinopathy.
Control subjects were type 2 diabetic pa-
tients of the same geographic origin with
urinary albumin concentrations 20
mg/l or 30 mg/24 h on two of three sterile
urine collections who were not receiving
ACE inhibitors and/or angiotensin recep-
tor blockers and who had retinopathy
and/or known diabetes duration 20
years.
The DIAB2NEPHROGENE and SUR-
DIAGENE studies were approved by the
Poitiers University Ethics Committee.
All participants gave written informed
consent.
Biological determinations
DNA extraction and genotyping methods
have been described elsewhere (13). A1C
was determined centrally using a high-
performance liquid chromatography
method: a DIAMAT analyzer (normal val-
ues 4.0–5.6%; Bio-Rad, Richmond, CA)
in the DIABHYCAR study and ADAMS
A1C HA-8160 analyzer (normal values
4.0–6.0%; Menarini, Florence, Italy), in
the DIAB2NEPHROGENE and SURDI-
AGENE studies. Urinary albumin was
measured by nephelometry. Serum creat-
inine, lipid (total and HDL cholesterol,
triglycerides, and calculated LDL choles-
terol), and highly sensitive C-reactive
protein concentrations were determined
centrally in the fasting state using a color-
imetric method, running on an auto-
mated analyzer (Kone Optima; Thermo
Clinical Labsystems, Vantaa, Finland),
and a nephelometric method (N High
Sensitivity CRP; Dade Behring, Marburg,
Germany), respectively.
Statistical analysis
In the DIABHYCAR and SURDIAGENE
studies, we considered the time to occur-
rence of a predeﬁned combined primary
end point and of each of its components
during the study. For the combined end
point, we considered only the event that
occurred ﬁrst. A Kaplan-Meier survival
curve was constructed to assess the effect
ofACEgenotypeontheoccurrenceofend
points with time to the event as the out-
come variable and censoring at the end of
the study. A multivariate Cox propor-
tional hazards model was used to analyze
the effect of ACE genotype and other co-
variates on study outcomes. We also used

2 and 
2 for trend tests, ANOVA after
log-transformation if required, and mul-
ACE genotype: cardiovascular and renal outcome
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analyses were performed with Statview 5
(SAS Institute, Cary, NC).
RESULTS
DIABHYCAR trial
Baseline characteristics are presented ac-
cording to the ACE insertion/deletion
polymorphisminTable1.TheACEinser-
tion/deletion polymorphism was associ-
atedwithapersonalhistoryofmyocardial
infarction(
26.53;P0.038),withtheI
allele being more frequent among partic-
ipants with previous myocardial infarc-
tion than among others (49.4 vs. 40.6%,
P0.01).Thisassociationpersisted(P
0.0076) in multiple logistic regression
analysis after sex, systolic blood pressure,
serum creatinine concentration, urinary
albumin concentration, and HDL choles-
terol concentration were considered and
also after forcing age, A1C, and smoking
into the model.
During follow-up (median 4 years;
range 0–6 years), a primary outcome oc-
curred in 495 participants (Table 2). The
occurrence of the primary combined out-
comedidnotdifferamongACEgenotypes
(supplementalFig.1A,availableinanon-
line appendix), with no interaction with
treatmentgroup(ramiprilorplacebo).No
association was found regarding the inci-
Table 1—Baseline clinical and biological characteristics according to the ACE insertion/deletion polymorphism in the DIABHYCAR trial
population
ACE genotype P value: II vs.
ID vs. DD ACE II ACE ID ACE DD
n 549 1,463 1,114
Randomization group (placebo/ramipril) 272 (50)/277 (50) 723 (49)/740 (51) 582 (52)/532 (48) 0.327
Age (years) 65.3  8.3 65.7  8.4 65.7  8.2 0.621
Sex (male/female) 395 (72)/154 (28) 1,061 (73)/402 (27) 828 (74)/286 (26) 0.481
Known diabetes duration (years) 10.1  7.6 10.3  7.7 10.2  7.8 0.802
Systolic blood pressure (mmHg) 145  15 145  14 144  14 0.331
Diastolic blood pressure (mmHg) 82  88 2  88 2  9 0.601
BMI (kg/m²) 29.6  4.6 29.3  4.6 29.3  5.0 0.460
Baseline urinary albumin (mg/l) 81 (42–227) 75 (40–175) 75 (39–183) 0.281
Smokers (yes/no)† 80 (17)/401 (83) 201 (16)/1,054 (84) 168 (18)/789 (82) 0.481
Serum creatinine (mol/l) 88  19 90  21 89  20 0.224
A1C (%) 8.0  1.8 7.9  1.7 7.8  1.8 0.016
Total cholesterol (mmol/l) 5.9  1.1 5.8  1.1 5.8  1.1 0.239
LDL cholesterol (mmol/l) 3.6  0.9 3.5  0.9 3.5  0.9 0.601
HDL cholesterol (mmol/l) 1.3  0.3 1.3  0.4 1.3  0.4 0.940
Total triglycerides (mmol/l) 1.9 (1.3–2.8) 1.8 (1.3–2.7) 1.8 (1.3–2.6) 0.564
C-reactive protein (mg/l) 2.9 (1.4–6.6) 3.1 (1.4–6.5) 3.2 (1.5–7.0) 0.438
Personal history of myocardial infarction
(yes/no)
39 (7)/510 (93) 85 (6)/1,378 (94) 47 (4)/1,067 (96) 0.0108
Personal history of stroke (yes/no) 17 (3)/532 (97) 59 (4)/1,404 (96) 45 (4)/1,069 (96) 0.4212
Data are expressed as means  SD, *medians (25th–75th percentile), or n (%). †Missing data for 433 patients.
Table2—Incidenceofthecombinedprimaryendpointandofeachofitsvariouscomponents,andall-causedeathduringtheDIABHYCARtrial
according to the ACE insertion/deletion polymorphism
Study end point All patients
ACE genotype P value (log-rank):
II vs. ID vs. DD ACE II ACE ID ACE DD
n enrolled 3,126 549 1,463 1,114
Primary combined end
point
495/3.78 (3.45–4.10) 97/4.20 (3.38–5.02) 230/3.76 (3.28–4.23) 168/3.60 (3.06–4.23) 0.489
Cardiovascular death 208/1.52 (1.31–1.72) 48/1.99 (1.43–2.55) 84/1.30 (1.02–1.58) 76/1.56 (1.22–1.91) 0.060
Myocardial
infarction (fatal and
nonfatal)
95/0.69 (0.55–0.83) 18/0.74 (0.40–1.09) 49/0.76 (0.55–0.97) 28/0.58 (0.36–0.79) 0.493
Stroke (fatal and nonfatal) 157/1.17 (0.98–1.35) 32/1.36 (0.89–1.82) 73/1.15 (0.89–1.42) 52/1.09 (0.79–1.38) 0.615
Heart failure requiring
hospitalization
136/1.00 (0.84–1.17) 21/0.89 (0.51–1.27) 67/1.06 (0.80–1.31) 48/0.99 (0.71–1.26) 0.769
ESRF 18/0.13 (0.07–0.19) 7/0.29 (0.07–0.51) 8/0.12 (0.04–0.21) 3/0.06 (0.01–0.13) 0.034
Death (all-cause) 455/3.13 (3.01–3.61) 88/3.68 (2.92–4.43) 191/2.95 (2.53–3.36) 176/3.61 (3.09–4.14) 0.071
Data are expressed as n or number of events per 100 patient-years (95% CI). Primary combined end point: time to cardiovascular death, nonfatal myocardial
infarction, nonfatal stroke, nonfatal heart failure requiring hospitalization, or ESRF.
Hadjadj and Associates
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1849dence of cardiovascular death, myocar-
dial infarction, stroke, and heart failure
leading to hospitalization (supplemental
Fig. 1B–E). However, the ACE genotype
affected the risk of ESRF (supplemental
Fig. 1F) with fewer occurrences of ESRF
among patients with the ID or the DD
than the II genotype (P  0.034). Results
were not affected by multivariate adjust-
ment (supplemental Table 1, available in
the online appendix); a higher risk for
ESRF persisted for the II genotype (P 
0.018).
Eleven of the 95 myocardial infarctions
occurringduringthetrialwerefatal:1ofthe
18patientswiththeIIgenotype,3ofthe49
patients with the ID genotype, and 7 of the
28 patients with the DD genotype (
2 for
trend P  0.024). D allele frequency was
0.85 in those with fatal myocardial infarc-
tions and 0.52 in those with nonfatal myo-
cardial infarctions (P  0.005). The
deleterious effect of the DD genotype on
postmyocardial infarction mortality risk
persisted in multivariate regression analysis
(adjusted relative risk vs. ID or II genotype
9.62 [95% CI 2.11–43.9]) (supplemental
Table 2, available in the online appendix).
Updated power calculation. Given the
observed incidence of the primary out-
come of 15.8% (495 events in 3,126 sub-
jects), the study had 80% power for
detecting a 25% difference between the
event rates in the 1,114 patients with the
DD genotype and the 2,012 patients with
the II or ID genotype.
SURDIAGENE cohort
The baseline characteristics of the 917
participants according to the ACE inser-
tion/deletion polymorphism are pre-
sented in Table 3. No association was
found between the ACE insertion/
deletion polymorphism and diabetic
nephropathy or personal history of myo-
cardial infarction.
Median follow-up was 3 years (range
0–6 years). A primary event occurred in
191 participants, and 108 patients died
(Table 4). The occurrence rate of the pri-
mary combined end point did not differ
Table 3—Baseline clinical and biological characteristics according to the ACE insertion/deletion polymorphism in the SURDIAGENE
population
ACE genotype P value: II vs.
ID vs. DD ACE II ACE ID ACE DD
n 118 448 351
Age (years) 66.1  10.4 65.2  10.6 64.9  10.4 0.604
Sex (male/female) 68 (58)/50 (42) 258 (58)/190 (42) 184 (52)/167 (48) 0.310
Known diabetes duration (years) 15.2  9.7 15.1  10.1 15.4  10.0 0.909
Systolic blood pressure (mmHg) 131  16 135  18 135  19 0.103
Diastolic blood pressure (mmHg) 72  10 73  11 73  11 0.709
BMI (kg/m²) 31.0  6.8 31.0  5.8 31.1  6.0 0.923
Baseline urinary albumin (mg/l) 22 (8–95) 23 (8–129) 25 (8–135) 0.841
Smokers (yes/no)* 10 (8)/107 (92) 52 (12)/389 (88) 30 (8)/317 (92) 0.288
Serum creatinine (mol/l) 81.5 (72–100) 84.5 (70–104) 84 (70–102) 0.488
A1C (%) 7.8  1.5 7.9  1.5 7.9  1.5 0.673
Personal history of myocardial
infarction (yes/no)
11 (9)/107 (91) 62 (14)/386 (86) 60 (17)/291 (83) 0.099
Personal history of stroke (yes/no) 4 (3)/114 (97) 21 (5)/427 (95) 19 (5)/332 (95) 0.665
ESRD† 2 (2)/116 (98) 6 (1)/442 (99) 7 (2)/344 (98) 0.774
Data are expressed as means  SD, medians (25th–75th percentile), or n (%). *Missing data for 12 patients. †Percent calculated among nephropathic patients.
Table 4—Incidence of the combined primary end point and of each of its various components, and all-cause death according to the ACE
insertion/deletion polymorphism in the SURDIAGENE cohort
Study end point All patients
ACE genotype P value (log-rank):
II vs. ID vs. DD ACE II ACE ID ACE DD
n enrolled 917 118 448 351
Primary combined end
point
187/7.28 (6.28–8.29) 26/8.32 (5.26–11.39) 90/7.11 (5.70–8.53) 71/7.18 (5.57–8.78) 0.769
Cardiovascular death 73/2.68 (2.07–3.28) 15/4.57 (2.31–6.83) 29/2.14 (1.37–2.91) 29/2.77 (1.77–3.77) 0.057
Myocardial infarction
(fatal and nonfatal)
31/1.15 (0.75–1.55) 5/1.53 (0.19–2.86) 14/1.04 (0.50–1.59) 12/1.16 (0.50–1.81) 0.771
Stroke (fatal and nonfatal) 25/0.92 (0.56–1.28) 3/0.91 (0.11–1.94) 11/0.81 (0.33–1.30) 11/1.06 (0.43–1.68) 0.842
Heart failure requiring
hospitalization
70/2.63 (2.02–3.23) 11/3.45 (1.44–5.45) 29/2.18 (1.40–2.97) 30/2.95 (1.91–3.99) 0.358
ESRF 26/0.97 (0.60–1.34) 2/0.61 (0.03–1.46) 15/1.13 (0.56–1.70) 9/0.87 (0.30–1.43) 0.633
Death (all-cause) 108/3.93 (3.20–4.65) 20/6.04 (3.47–8.61) 45/3.29 (2.34–4.23) 43/4.08 (2.89–5.28) 0.125
Dataarenandnumberofeventsper100patient-years(95%CI).Primarycombinedendpoint:timetocardiovasculardeath,nonfatalmyocardialinfarction,nonfatal
stroke, nonfatal heart failure requiring hospitalization, or ESRF.
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wasfoundfortheincidenceofmyocardial
infarction, stroke, heart failure leading to
hospitalization, and ESRF. However, car-
diovascular death occurred more fre-
quently in patients with the II genotype
comparedwithpatientswiththeIDorDD
genotypes (P  0.057).
Eightofthe31patientshavingamyo-
cardial infarction during the follow-up
period died: none of the 5 patients with
the II genotype, 3 of the 14 patients with
the ID genotype, and 5 of the 12 patients
with the DD genotype (
2 for trend P 
0.0631). D allele frequency was 0.81 in
those having fatal myocardial infarctions
and 0.54 in those having nonfatal myo-
cardial infarctions (P  0.057). The dele-
terious effect of the DD genotype on
postmyocardial infarction mortality risk
was not signiﬁcant (relative risk vs. ID or
II genotype 2.16 [95% CI 0.60–7.79]).
DIAB2NEPHROGENE study
Weconsideredatotalof863casepatients
and 414 control subjects. Their baseline
characteristics are summarized according
to the ACE insertion/deletion polymor-
phismsinsupplementalTable3.Noasso-
ciation was found between the ACE
insertion/deletion polymorphism and di-
abetic nephropathy or ESRF. The ACE in-
sertion/deletion polymorphism was not
signiﬁcantly associated with a personal
history of myocardial infarction (data not
shown).
CONCLUSIONS — The data from
our large-scale trial suggest that the ACE
genotypeintype2diabeticpatientswitha
high cardiovascular and renal risk is of
little value for the determination of prog-
nosis. We found that the ACE insertion/
deletion genotype had no impact on the
occurrence of a composite end point in-
cluding cardiovascular death, myocardial
infarction, stroke, heart failure leading to
hospitalization,andESRF.Thelackofim-
pact of the ACE insertion/deletion poly-
morphism on the global cardiorenal
prognosis of type 2 diabetic subjects was
replicated in two additional cohorts.
These are the ﬁrst prospective follow-up
studies on the impact of the ACE inser-
tion/deletion polymorphism on cardio-
vascular and renal outcomes in people
with type 2 diabetes.
French participants in the DIABHY-
CAR trial were enrolled by their general
practitioners.ThisensuredthattheDIAB-
HYCAR cohort was representative, as
90% of French individuals with type 2
diabetes are treated by their general prac-
titioners. In contrast, the participants
in the other two studies were recruited
from hospitals (SURDIAGENE and
DIAB2NEPHROGENE) and more fre-
quently had cardiovascular diseases. This
difference in the prevalence of complica-
tions between hospital-based and popu-
lation-based studies has been reported
before (21).
The ACE insertion/deletion polymor-
phism appeared ideal to introduce some
genetic components into the calculation
of cardiovascular and renal risks, particu-
larly in type 2 diabetes. However, the
present results do not support this possi-
bility. Thus, the widespread use of this
polymorphismforindividualizingcardio-
vascular and renal prognoses in type 2
diabetes seems ruled out by our ﬁndings.
The association between the ACE I al-
leleandpreviousmyocardialinfarctionin
DIABHYCAR participants went against
our hypothesis, although it was not repli-
cated in the other two cohorts. For myo-
cardial infarction, conﬂicting data have
been obtained in case-control studies
(11,12). However, we must consider the
possibilitythataselectionbiasmighthave
been operating in DIABHYCAR, in which
the I allele was unexpectedly related to a
history of myocardial infarction. This
ﬁndingdidnotﬁtwiththeso-calledmen-
delian randomization principle. In DIAB-
HYCAR and SURDIAGENE, death after
myocardialinfarctionwasrelatedtotheD
allele. Only small numbers of events were
recorded, but ACE D allele frequency was
higher in those dying after myocardial in-
farction (79 vs. 55%); this difference was
signiﬁcant (P  0.005) when the two
studies were pooled. This result is consis-
tent with an autopsy study conducted in
Belfast: individuals who died of coronary
heart disease displayed the DD genotype
more frequently than the ID or II geno-
types (22). Thus, we can speculate that
type 2 diabetic patients with the highest
cardiovascularrisk,favoredbytheDDge-
notype, were not included in the DIAB-
HYCAR trial because of premature death.
This may account for the statistically sig-
niﬁcant but not clinically valuable associ-
ation between the ACE D allele and
myocardial infarction reported in a meta-
analysis of several cross-sectional studies
(12). However, these are only secondary
end points, and this analysis should be
considered as exploratory only.
We and others have shown through
follow-up and experimental studies (14–
16) that the ACE II genotype protects
against renal failure in type 1 diabetes.
The association of the II genotype with
ESRF in DIABHYCAR, contradicting this
hypothesis, was not replicated in the
SURDIAGENEcohort.Thus,thepossibil-
ity of a chance ﬁnding is likely. As previ-
ously suggested for Caucasians (23), our
results do not support the theory that re-
nal involvement is related to the ACE in-
sertion/deletion polymorphism in type 2
diabetes, contrary to type 1 diabetes.
In summary, we were not able to
identify the ACE insertion/deletion poly-
morphism as a marker for the cardiovas-
cular and renal prognosis of patients with
type2diabetes,evenifaneffectofmodest
amplitude could have been missed owing
to insufﬁcient statistical power. Although
of great interest for pathophysiological
studies,thisgeneticvariantdoesnotseem
ready for use in routine clinical practice.
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